A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose- Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects With Previously Treated Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2018
At a glance
- Drugs GBR 1342 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 06 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 11 Dec 2017 According to a Glenmark Pharmaceuticals media release, first patient has been dosed.
- 14 Nov 2017 Status changed from not yet recruiting to recruiting.